On December 19, 2024, the final agreement was signed for the sale of specific Peruvian intellectual property assets, market authorizations, and inventory of Teva Perú S.A. (Teva), a subsidiary of Teva Pharmaceuticals, to an international group with investments in the pharmaceutical industry. Following the satisfaction of certain conditions, the transaction closed on January 21, 2025.
The transaction terms include a manufacturing agreement under which Teva will temporarily produce and supply certain pharmaceutical products, as well as a pharmacovigilance agreement.
The value of the deal remains confidential.